CoChat

Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China

Open access

The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: This study aimed to evaluate the long-term cost-effectiveness of once-weekly subcutaneous semaglutide versus polyethylene glycol loxenatide (PEG-loxenatide) in patients with type 2 diabetes uncontrolled on metformin, from a Chinese healthcare systems perspective. METHODS: The study applied the Swedish Institute of Health Economics Diabetes Cohort Model to evaluate the long-term clinical and economic outcomes of once-weekly treatment of semaglutide at 0.5 mg and 1.0 mg, respectively, versus PEG-loxenatide 0.2 mg, over a 40-year time horizon. Baseline cohort characteristics were collected from the SUSTAIN China trial. A network meta-analysis was conducted to obtain comparative treatment effects of once-weekly semaglutide and PEG-loxenatide based on two phase 3a clinical trials. Drug costs were sourced from the national bidding price of China. Outcomes were discounted at 5.0% per annum. One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to assess the uncertainty of the base-case results. RESULTS: When compared with PEG-loxenatide 0.2 mg, the projections of outcomes over the 40-year time horizon in patients with type 2 diabetes uncontrolled on metformin showed that treatment with once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improved discounted life expectancy by 0.08 and 0.12 years, and improved discounted quality-adjusted life expectancy by 0.16 and 0.22 quality-adjusted life-years, respectively. Once-weekly semaglutide 0.5 mg and 1.0 mg were achieved at lifetime cost savings of 19,309 China Yuan (CNY) and 10,179 CNY, respectively. Sensitivity analyses verified the robustness of the results. CONCLUSION: From the perspective of Chinese healthcare systems, treatment with once-weekly subcutaneous semaglutide represents a dominant option versus PEG-loxenatide for patients with type 2 diabetes uncontrolled on metformin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-022-01336-7

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mean direct cost over a patient’s lifetime (in 2021 Chinese Yuan [CNY])
Fig. 1 Mean direct cost over a patient’s lifetime (in 2021 Chinese Yuan [CNY])CC BY-NC · PubMed Central
Fig. 2 Probabilistic sensitivity analyses scatter plot of once-weekly semaglutide 0.5 mg vs. polyethylene glycol loxenatide 0.2 mg (a) and once-weekly semaglutide 1.0 mg vs. polyethylene glycol loxenatide 0.2 mg (b)
Fig. 2 Probabilistic sensitivity analyses scatter plot of once-weekly semaglutide 0.5 mg vs. polyethylene glycol loxenatide 0.2 mg (a) and once-weekly semaglutide 1.0 mg vs. polyethylene glycol loxenatide 0.2 mg (b)CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Research works printed but not linked: 8

  1. Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellit. 2021;13(04):315–409.
  2. International Diabetes Federation. IDF Diabetes atlas. 2019. https://diabetesatlas.org/atlas/ninth-edition/. Accessed 2 June 2022.
  3. Shen Y, Li F, Zhu B, et al. Accounting and analysis of curative expenditure on diabetes treatment of Shanghai in 2018. Chin Health Econ. 2022;3(41):56–9.
  4. Liu GG. China guidelines for pharmacoeconomic evaluations. Beijing: China Market Press; 2020.
  5. Wu J, He X, Liu Y. Cost-effectiveness analysis of insulin aspart 30 versus insulin glargine in patients with type 2 diabetes in China. Chin Pharm J. 2016;51(3):242–7.
  6. Cai X, Yang W, Gao X, Zhou L, Han X, Ji L. Meta-analysis of the insulin dosage in Chinese type 2 diabetic patients receiving insulin treatment. Chin J Diabetes. 2016;24(6):490–507.
  7. He X, Zhang Y, Ruan Z, Li L, Wu J. The prevalence and related direct medical costs of chronic complications among patients with type 2 diabetes in China. Chin J Endocrinol Metab. 2019;3(35):200–5.
  8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1988;352(9131):837–53.

Cited by

See all 12

Metadata

Authors
Liu, L., Ruan, Z., Ung, C. O. L., Zhang, Y., Shen, Y., Han, S., Jia, R., Qiao, J., Hu, H., & Guo, L.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • University of Macau (MO)
  • Peking University (CN)
  • University College London (GB)
Corresponding author
  • Hu, Hao
  • Guo, Lixin
Venue
Diabetes Therapy
Published
2022-11-22
Volume
14
Issue
1
Pages
93-107
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4309674065
Cited by
12
References
60
Citations by year
2026: 4 · 2025: 1 · 2024: 6 · 2023: 1
FWCI
1.48
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Novo Nordisk
  • Universidade de Macau
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
semaglutide, type 2 diabetes, cost-effectiveness, GLP-1 receptor agonists, quality-adjusted life years, Chinese healthcare system, cohort model

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China. https://app.cochat.ai/papers/10.1007/s13300-022-01336-7
The paper
Liu, L., Ruan, Z., Ung, C. O. L., Zhang, Y., Shen, Y., Han, S., Jia, R., Qiao, J., Hu, H., & Guo, L. (2023). Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China. Diabetes Therapy. https://doi.org/10.1007/s13300-022-01336-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.